Medical, News Headlines

Rat Tests Show HairLoss Reduction After Cancer Treatment

Rat Tests Show HairLoss Reduction After Cancer Treatment

New York, 03, 2020:  A 12-week study by Hoth Therapeutics suggests the potential of WEG232,WEG232 a topical treatment for hair loss in reducing the side effects of Erlotinib. Erlotinib is a frequently used agent that combats several cancers but can result in serious side effects including hair loss.  The research with 25 SD-rats, took place at George Washington University and indicated that topical application of WEG232 could be effective in suppressing erlotinib induced-facial rash/hair loss. Roth CEO, Robb Knie, commented, “This study showed compelling results with a 71% facial rash and hair loss reduction.”

3 thoughts on “Rat Tests Show HairLoss Reduction After Cancer Treatment”

  1. David John says:

    Hairloss research has never been more prolific. it is especially sad that after facing a disease like Cancer people have to deal with hairloss as well. It will take time, but hopefully this latest study will provide some relief.

  2. Hairauthority says:

    Yes,it is a devastating and we hope that researchers are already working on finding a way to handle this.

  3. Nick Sams says:

    Interesting !